TScan Therapeutics reports a 30% reduction in its workforce, eliminating approximately 66 employees, to concentrate resources on its heme program after a positive end‑of‑Phase 1 meeting with the U.S. Food and Drug Administration that confirmed the regulatory path for its TSC‑101 candidate for acute myeloid leukemia and myelodysplastic syndromes.
The company pauses enrollment in its solid‑tumor Phase 1 trial and redirects pre‑clinical work toward in‑vivo engineered TCR‑T therapies and autoimmunity target discovery, aiming to accelerate the pivotal study for TSC‑101 and reduce operating costs by focusing on the most promising therapeutic area.
Financially, the restructuring is expected to generate about $45 million in annual cost savings in 2026 and 2027, extending the cash runway into the second half of 2027. A one‑time charge of up to $2.3 million is anticipated in Q4 2025 for severance‑related benefits and other costs. In the third quarter of 2024, the company reported revenue of $1.0 million versus $3.9 million in Q3 2023, and a net loss of $29.9 million versus $23.0 million in Q3 2023.
TScan highlights a commercial‑ready manufacturing process that shortens production time for TSC‑101 from 17 to 12 days, potentially lowering costs and improving patient outcomes. The reduction addresses concerns about prolonged chimerism and relapse associated with products requiring higher T‑cell expansion.
Management notes that the FDA’s confirmation of the pivotal trial design for TSC‑101 supports the strategic shift, and the company plans to submit an IND for expanded HLA coverage in Q4 2025, present data at ASH in December 2025, and release initial PLEXI‑T data in Q1 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.